 Principal secondary efficacy end-points: 1: percent of time in hyperglycemia 1.8 gl and in hypoglycaemia 0.5gl between time of intervention and 48 hours after the first device calibration. 2: composite criterion evaluated one month after inclusion: death or cardiovascular event events acute coronary syndromes, heart failure, arrhythmia stream infections, neurologic events. 3: agreement between CGM with Glucoday and conventional capillary blood glucose monitoring using coupled data recorded at the same time except couples of data corresponding to calibration time T0, T24H. 4: duration of stay in hospital for the two randomization groups. 5: device and care tolerance by collection of all adverse events due to the device during the hospitalization. 